We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

38 hedge funds and large institutions have $374K invested in GT Biopharma in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

81% more funds holding

Funds holding: 21 → 38 (+17)

68% more capital invested

Capital invested by funds: $222K → $374K (+$152K)

5.98% less ownership

Funds ownership: 10.52% → 4.54% (-6%)

63% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 8

Holders
38
Holders Change
+17
Holders Change %
+80.95%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
3
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SRL
Scientech Research LLC
New Jersey
+$38.9K
2
SWM
SeaCrest Wealth Management
New York
+$35.5K
3
Citadel Advisors
Citadel Advisors
Florida
+$29.2K
4
Jane Street
Jane Street
New York
+$18.5K
5
IWC
Integrated Wealth Concepts
Massachusetts
+$14.2K

Top Sellers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
-$83.5K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$58K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$6.25K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$3.34K
5
TSS
Two Sigma Securities
New York
-$3.22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$2.18K +$1.98K +2,781 New
Osaic Holdings
27
Osaic Holdings
Arizona
$1.58K -$2.18K -3,073 -61%
CIBC Private Wealth Group
28
CIBC Private Wealth Group
Georgia
$1.57K +$1.42K +2,000 New
TRCT
29
Tower Research Capital (TRC)
New York
$1.34K -$2 -3 -0.2%
TCM
30
Triumph Capital Management
Colorado
$1.3K +$1.18K +1,655 New
SWM
31
Spire Wealth Management
Virginia
$785 +$706 +994 New
SC
32
Swan Capital
Florida
$785 +$710 +1,000 New
Bank of America
33
Bank of America
North Carolina
$19 – – –
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$13 – – –
UBS Group
35
UBS Group
Switzerland
$1 -$1.86K -2,625 -100%
SS
36
SBI Securities
Japan
$1 -$3 -4 -80%
AF
37
Allworth Financial
California
$1 – – –
JP Morgan Chase
38
JP Morgan Chase
New York
$1 – – –
DS
39
DRW Securities
Illinois
– -$83.5K -142,380 Closed
Vanguard Group
40
Vanguard Group
Pennsylvania
– -$6.25K -10,504 Closed
CA
41
Clearstead Advisors
Ohio
– -$508 -865 Closed
Jones Financial Companies
42
Jones Financial Companies
Missouri
– -$230 -300 Closed
BBPWM
43
Blue Bell Private Wealth Management
Pennsylvania
– -$6 -10 Closed
1
2

GTBP Hedge Fund Activity: Q4 2025 in Review

38 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2025, worth a combined $374K — up 68% from $222K a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new GTBP positions and 5 closed out — a net gain of 17 holders — while 3 added to existing stakes and 8 trimmed.

The largest buyer was Scientech Research LLC, opening a new position worth an estimated $38.9K. The largest seller was DRW Securities, exiting entirely with an estimated $83.5K sold.

  • 38 institutional investors held GT Biopharma (GTBP) as of Q4 2025, up from 21 in Q3 2025.
  • Funds reported $374K of GT Biopharma stock for Q4 2025, up 68% quarter-over-quarter.
  • 22 funds opened new GT Biopharma positions in Q4 2025 and 5 closed out, a net change of +17 holders.
  • The largest GT Biopharma buyer in Q4 2025 was Scientech Research LLC, an estimated $38.9K added.
  • The largest GT Biopharma seller in Q4 2025 was DRW Securities, an estimated $83.5K sold.

Based on aggregated 13F filings for Q4 2025.